文献速递糖尿病

2型糖尿病远端对称性多发性神经病变的时间趋势:弗里曼特尔糖尿病研究

Temporal Trends in Distal Symmetric Polyneuropathy in Type 2 Diabetes: The Fremantle Diabetes Study.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

在弗里曼特尔糖尿病研究I期(1993-1996年招募,n=1296)和II期(2008-2011年招募,n=1509)的社区2型糖尿病队列中,采用密歇根神经病变筛查仪(MNSI)评估远端对称性多发性神经病变(DSPN)。多变量分析显示,FDS2较FDS1的6点MNSI DSPN患病率更低(OR 0.68),但2点MNSI无显著差异;4年DSPN发病率在6点MNSI中FDS2更高(IRR 1.31),在2点MNSI中FDS2更低(IRR 0.53)。

要点

  • 8点MNSI DSPN患病率FDS1为30.8%,FDS2为58.9%(P<.001),因足部外观评估变化未进一步分析。
  • 6点MNSI DSPN患病率FDS1为37.5%,FDS2为35.7%(P=.336);2点MNSI为33.8%和38.7%(P=.011)。
  • 多变量模型中,FDS1与FDS2的DSPN患病与发病关联方向随MNSI特征不同而异。

核心结论

  • 在社区2型糖尿病澳大利亚人群中,FDS2较FDS1的DSPN患病率更低或相当,而发病率在6点MNSI中更高、在2点MNSI中更低,具体取决于所用的MNSI特征。

研究设计与样本

  • 观察性研究,在城市人群中进行,纳入弗里曼特尔糖尿病研究I期(FDS1;n=1296,1993-1996年招募)和II期(FDS2;n=1509,2008-2011年招募)的2型糖尿病患者。

主要发现

  • 8点MNSI DSPN患病率FDS1为30.8%,FDS2为58.9%(P<.001),因两期足部外观评估变化,8点MNSI数据未进一步分析。
  • 6点MNSI(排除足部外观)DSPN患病率FDS1为37.5%,FDS2为35.7%(P=.336);2点MNSI(仅生物振动觉)DSPN患病率FDS1为33.8%,FDS2为38.7%(P=.011)。
  • 多变量分析中,FDS2较FDS1与6点MNSI DSPN患病相关(OR 0.68,95%CI 0.56-0.83;P<.001),但与2点MNSI DSPN患病无显著关联(OR 0.90,95%CI 0.74-1.11;P=.326)。
  • 4年DSPN发病率(95%CI)在6点MNSI中FDS1为13.6(12.0-15.4)/100人年,FDS2为17.6(15.9-19.4)/100人年(IRR 1.31,95%CI 1.12-1.55;P<.001);在2点MNSI中FDS1为13.9(12.3-15.8)/100人年,FDS2为7.4(16.3-8.6)/100人年(IRR 0.53,95%CI 0.43-0.64;P<.001)。
  • FDS2较FDS1独立预测6点MNSI新发DSPN(HR 1.25,95%CI 1.06-1.48;P=.009)和2点MNSI新发DSPN(HR 0.42,95%CI 0.33-0.55;P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Macrovascular outcomes in type 2 diabetes have improved over recent decades. There are scant equivalent distal symmetric polyneuropathy (DSPN) data. OBJECTIVE: This work aimed to characterize temporal changes in DSPN prevalence and incidence rates (IRs) in community-based Australians. METHODS: An observational study was conducted among an urban population. Participants included individuals with type 2 diabetes from the Fremantle Diabetes Study phases I (FDS1; n = 1296 recruited 1993-1996) and II (FDS2; n = 1509 recruited 2008-2011). Main outcome measures included Michigan Neuropathy Screening Instrument (MNSI) clinical grading. RESULTS: DSPN prevalence by 8-point MNSI was 30.8% (FDS1) and 58.9% (FDS2; P < .001), and by 6-point (excluding foot appearance) and 2-point (biothesiometry alone) MNSI was 37.5% and 35.7% (P = .336), and 33.8% and 38.7% (P = .011), respectively. Given between-phase changes in appearance assessment, 8-point MNSI data were not analyzed further. In multivariable analysis, FDS2 vs FDS1 participation was associated with 6-point (odds ratio (95% CI) 0.68 (0.56-0.83); P < .001) but not 2-point (0.90 (0.74-1.11); P = .326) MNSI DSPN prevalence. Four-year DSPN IRs (95% CI) for 6-point MNSI were 13.6 (12.0-15.4) and 17.6 (15.9-19.4)/100 person-years in FDS1 and FDS2, respectively (IR ratio [IRR] 1.31 [1.12-1.55]; P < .001), and for 2-point MNSI were 13.9 (12.3-15.8) and 7.4 (16.3-8.6/100 person-years; IRR 0.53 [0.43-0.64]; P < .001). FDS2 vs FDS1 independently predicted incident DSPN for 6-point (hazard ratio [95% CI] 1.25 [1.06-1.48]; P = .009) and 2-point (0.42 [0.33-0.55]; P < .001) MNSI. CONCLUSION: DSPN prevalence was lower or equivalent in FDS2 vs FDS1, and its incidence was greater or lower, in multivariable models depending on the MNSI features used.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Davis WA, Hamilton E, Davis TME, et al. Temporal Trends in Distal Symmetric Polyneuropathy in Type 2 Diabetes: The Fremantle Diabetes Study. J Clin Endocrinol Metab. 2024. PMID: 37930807. doi:10.1210/clinem/dgad646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。